Report top-line data for the LYNX-1 Phase 3 trial
Not delivered by the deadline
AI-confirmed · human review in progress Independent AI checks agreed on primary SEC or regulator evidence. Records are now being reviewed by hand, starting with those our customers order.
- Announced
- 6 Jan 2021
- Due
- 30 Sep 2021
- Checked
- 25 Oct 2026
- Deadline
- Met
- Late
- Not met
- Today
What the company said
“Data expected in 3Q21 (n=160)”
What we found
Evidence strength A What the grades mean
The company did not report top-line data for the LYNX-1 trial by the 3Q21 deadline, subsequently pushing the expected reporting date to early 2022 and then to the second quarter of 2022.
-
A Ocuphire Pharma, Inc. 10-Q filed 2021-11-12
“Ocuphire also initiated a Phase 3 trial (LYNX-1) for the treatment of NVD in the fourth quarter of 2020; top-line data for this study are expected to be reported in early 2022.” ✓ confirmed on the page
Market reaction: the shares moved -1.7% against the S&P 500 over the three sessions around the disclosure (11 Nov 2021 to 16 Nov 2021). What this measures
Checked 25 Oct 2026.
Commitment DNA
The structured record of this commitment. Fields the company did not state are left blank rather than guessed.
- Event type
- Clinical readout late
- Indicative materiality
- High rules
- Action
- Report
- Deliverable
- LYNX-1 trial data
- Target
- 160 patients
- Language
- Expected (“expects”, “plans”)
- In the company’s control
- High
- Specificity
- High
How this entry was checked
- Commitment recordedThe company's words were matched word for word against the filing.
- First checkAn AI model, Gemini (Google), read the company's later filings and recorded the outcome with a quoted passage.
- Second check: agreesA different AI model, Claude (Anthropic), re-read the evidence without being told the outcome and reached the same answer.
- Third check on a negative finding: agreesBecause a negative finding could harm a company if wrong, a stronger model re-read the evidence fully blind and reached the same answer.
Confirmed. This outcome counts towards the company's Kept Score. How verification works
Are you Ocuphire Pharma, Inc.? You can publish an official statement next to this entry, free. Add a statement.
Is something here wrong or out of date? Companies and readers can ask us to check it. Please bring a link to a public source.
Report an error in this entry Reference: KI-C-2021-IRD-021109 · Corrections policy